Sandra E. Dillahunt

Array ( [id] => 7579677 [patent_doc_number] => 20110293560 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-12-01 [patent_title] => 'METHOD FOR DETERMINING IMMUNE SYSTEM ACTIVITY AND MEDICAMENT FOR INFLUENCING SAME' [patent_app_type] => utility [patent_app_number] => 13/099185 [patent_app_country] => US [patent_app_date] => 2011-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 6953 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0293/20110293560.pdf [firstpage_image] =>[orig_patent_app_number] => 13099185 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7499309 [patent_doc_number] => 20110262398 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-10-27 [patent_title] => 'CARDIAC TREATMENT USING ANTI-FIBROTIC AGENTS' [patent_app_type] => utility [patent_app_number] => 13/091972 [patent_app_country] => US [patent_app_date] => 2011-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 12682 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0262/20110262398.pdf [firstpage_image] =>[orig_patent_app_number] => 13091972 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8779573 [patent_doc_number] => 20130101548 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-04-25 [patent_title] => 'Whey Protein Isolate Hydrogels and Their Uses' [patent_app_type] => utility [patent_app_number] => 13/637699 [patent_app_country] => US [patent_app_date] => 2011-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 37 [patent_no_of_words] => 24283 [patent_no_of_claims] => 61 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13637699 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7697066 [patent_doc_number] => 20110229524 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-09-22 [patent_title] => 'Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of Gastric Cancer and other cancers' [patent_app_type] => utility [patent_app_number] => 13/051568 [patent_app_country] => US [patent_app_date] => 2011-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 35082 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0229/20110229524.pdf [firstpage_image] =>[orig_patent_app_number] => 13051568 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6101690 [patent_doc_number] => 20110165182 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-07-07 [patent_title] => 'CONJUGATE OF AN ANTIBODY AGAINST CCR5 AND AN ANTIFUSOGENIC PEPTIDE' [patent_app_type] => utility [patent_app_number] => 13/050615 [patent_app_country] => US [patent_app_date] => 2011-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 15607 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0165/20110165182.pdf [firstpage_image] =>[orig_patent_app_number] => 13050615 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8828677 [patent_doc_number] => 20130129723 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-05-23 [patent_title] => 'Heterodimer Binding Proteins and Uses Thereof' [patent_app_type] => utility [patent_app_number] => 13/519727 [patent_app_country] => US [patent_app_date] => 2010-12-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 45790 [patent_no_of_claims] => 54 [patent_no_of_ind_claims] => 19 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13519727 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8483722 [patent_doc_number] => 20120283128 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-11-08 [patent_title] => 'METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE' [patent_app_type] => utility [patent_app_number] => 13/517244 [patent_app_country] => US [patent_app_date] => 2010-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37021 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13517244 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8320873 [patent_doc_number] => 20120193291 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-08-02 [patent_title] => 'MUTANT PTP ALPHA GENE GROUP IN MALIGNANT TUMORS AND PRODUCTION METHOD' [patent_app_type] => utility [patent_app_number] => 13/383065 [patent_app_country] => US [patent_app_date] => 2010-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 3576 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13383065 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11611532 [patent_doc_number] => 09649374 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-05-16 [patent_title] => 'Neutralizing prolactin receptor antibodies and their therapeutic use' [patent_app_type] => utility [patent_app_number] => 13/514992 [patent_app_country] => US [patent_app_date] => 2010-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 30 [patent_no_of_words] => 30297 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 171 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13514992 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8465615 [patent_doc_number] => 20120270782 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-10-25 [patent_title] => 'FORMULATION FOR HGH AND RHIGF-1 COMBINATION' [patent_app_type] => utility [patent_app_number] => 13/513858 [patent_app_country] => US [patent_app_date] => 2010-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 10135 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13513858 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6212337 [patent_doc_number] => 20110135637 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-06-09 [patent_title] => 'TRIMODAL CANCER THERAPY' [patent_app_type] => utility [patent_app_number] => 12/947362 [patent_app_country] => US [patent_app_date] => 2010-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13011 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0135/20110135637.pdf [firstpage_image] =>[orig_patent_app_number] => 12947362 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6118574 [patent_doc_number] => 20110076247 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-03-31 [patent_title] => 'AGENT COMPRISING G-CSF FOR PREVENTION AND TREATMENT OF DIABETIC PERIPHERAL NEUROPATHY' [patent_app_type] => utility [patent_app_number] => 12/915172 [patent_app_country] => US [patent_app_date] => 2010-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 4248 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0076/20110076247.pdf [firstpage_image] =>[orig_patent_app_number] => 12915172 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10621668 [patent_doc_number] => 09340605 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-05-17 [patent_title] => 'VHH for application in tissue repair, organ regeneration, organ replacement and tissue engineering' [patent_app_type] => utility [patent_app_number] => 13/503355 [patent_app_country] => US [patent_app_date] => 2010-10-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 22 [patent_no_of_words] => 17652 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 92 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13503355 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9950559 [patent_doc_number] => 08999342 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-04-07 [patent_title] => 'Anti-fibroblast activation protein antibodies and methods and uses thereof' [patent_app_type] => utility [patent_app_number] => 13/499718 [patent_app_country] => US [patent_app_date] => 2010-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 23910 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13499718 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8416641 [patent_doc_number] => 20120244142 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-09-27 [patent_title] => 'ANTIBODY CAPABLE OF RECOGNIZING HLA CLASS I' [patent_app_type] => utility [patent_app_number] => 13/497545 [patent_app_country] => US [patent_app_date] => 2010-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 12244 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13497545 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8313050 [patent_doc_number] => 20120190044 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-07-26 [patent_title] => 'METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE' [patent_app_type] => utility [patent_app_number] => 13/497514 [patent_app_country] => US [patent_app_date] => 2010-09-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 60339 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13497514 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8950103 [patent_doc_number] => 20130195883 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-08-01 [patent_title] => 'USE OF VAP-1 INHIBITORS FOR TREATING FIBROTIC CONDITIONS' [patent_app_type] => utility [patent_app_number] => 13/395029 [patent_app_country] => US [patent_app_date] => 2010-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 10995 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13395029 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9440315 [patent_doc_number] => 08709424 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-04-29 [patent_title] => 'Anti-GITR antibodies' [patent_app_type] => utility [patent_app_number] => 13/388270 [patent_app_country] => US [patent_app_date] => 2010-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 22458 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13388270 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8335170 [patent_doc_number] => 20120201873 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-08-09 [patent_title] => 'CONTROLLED RELEASE FORMULATIONS OF LIPOCALIN MUTEINS' [patent_app_type] => utility [patent_app_number] => 13/388788 [patent_app_country] => US [patent_app_date] => 2010-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 19884 [patent_no_of_claims] => 41 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13388788 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8482878 [patent_doc_number] => 20120282285 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-11-08 [patent_title] => 'MASP ISOFORMS AS INHIBITORS OF COMPLEMENT ACTIVATION' [patent_app_type] => utility [patent_app_number] => 13/383676 [patent_app_country] => US [patent_app_date] => 2010-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 36 [patent_no_of_words] => 28053 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 14 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13383676 [rel_patent_id] =>[rel_patent_doc_number] =>)